Alphabet Inc.'s (NASDAQ: GOOG) Google Cloud introduced two new AI-powered tools that hold the potential to revolutionize the drug development process for biotech and pharmaceutical companies.

After years of development, Isomorphic Labs says its AI-created drugs are nearly ready for human trials. Isomorphic Labs, the AI-powered drug company spun out of Google’s DeepMind, just announced that ...

A secretive, Google-backed lab is using artificial intelligence to invent new medicines for humanity's worst illnesses. But ...

Google DeepMind has announced the launch of TxGemma, an open collection of AI models designed to enhance the efficiency of drug discovery and clinical trial predictions.Built on the Gemma model ...

Alphabet’s AI-powered drug discovery company, Isomorphic Labs, is preparing to take its first major leap into the real world.

Google DeepMind's drug discovery company, Isomorphic Labs, is gearing up to launch the human trials of its AI-designed drugs.

In an industry where 90 percent of drug candidates fail before reaching the market, a handful of startups are betting ...

Ginkgo Bioworks introduces a protein large language model and API, developed with Google Cloud, to streamline drug discovery by leveraging AI and proprietary biological data, offering affordable ...

Isomorphic Labs, which uses artificial intelligence technologies for drug discovery, has raised $600 million in its first ever external funding round led by Thrive Capital, the startup said on Monday.

Pharmaceutical company Servier has selected Google Cloud for its "digital transformation" as it aims to use high-performance computing and artificial intelligence to further its data analysis and ...

Google Ventures and Alphabet, an existing investor, also participated in the round. Top tech companies are racing to position AI-powered offerings as central to their products and services.